ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026
Analyses of plasma multi-omic data across ancestries identify novel pathways implicated in Alzheimer's disease.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Plasma proteomic profiles of Alzheimer's disease and neurodegeneration in African cohorts.Nature communications · 2026Article
- Analyses of plasma multi-omic data across ancestries identify novel pathways implicated in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
introductionFew genetic studies on Alzheimer's disease (AD) have incorporated multiple ancestries and omic datasets to pinpoint actionable AD risk effectors for each ancestry.
methodsHere, we first performed genetic colocalization between molecular phenotypes (proteomics and metabolomics) from two ancestral groups (European [EUR] and African [AFR]) and the two largest EUR AD genome-wide association studies. We next performed pathway enrichment analyses to identify biological mechanisms.
resultsWe found 21 proteins and one metabolite colocalized with AD risk that were shared between the EUR and AFR ancestry groups. We also identified 25% AFR and 60% EUR proteins; 50% AFR and 10% EUR metabolites were unique. The pathway enrichment analyses nominated interleukin-1 production and lipid pathway were shared underlying proteomic and metabolomic findings, respectively. DISCUSSION: Our findings indicate that these four plasma datasets may pinpoint different effectors of AD risk in diverse populations; findings from AFR participants require validation with AFR-based genome-wide association study data. HIGHLIGHTS: For proteomics, 61% of findings for European (EUR) ancestry and 72% for African (AFR) ancestry were not previously reported. For metabolomics, 83% of findings for EUR ancestry and 50% AFR ancestry were not previously reported. Both convergent and divergent pathways were identified in EUR- and AFR-ancestry stratified analyses in either proteomics or metabolomics findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.